Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study.

ABSTRACT:

Background

This subanalysis of BENEFIT-KOREA cohort assessed the impact of baseline pulse rate (PR) and posttreatment PR reduction on the blood pressure (BP)-lowering efficacy of nebivolol in patients with hypertension.

Methods

South Korean patients with hypertension were enrolled in the BENEFIT-KOREA study; 3,011 patients received nebivolol as monotherapy/add-on therapy. Time-averaged BP, calculated by sum of the product of BPs at weeks 12 and 24 corrected for number of participants at these timepoints, was evaluated with/without adjustment for baseline BP. Change in BP in baseline PR groups of < 70, 70-79, and ≥ 80 beats/min and posttreatment PR reduction groups of < 1, 1-9, and ≥ 10 beats/min at 24 weeks were evaluated.

Results

The unadjusted time-averaged systolic

SUBMITTER: Shin J 

PROVIDER: S-EPMC11903211 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature